Loading clinical trials...
Loading clinical trials...
A Phase 1 Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants
Conditions
Interventions
PGDM1400LS (5mg/kg, IV)
PGDM1400LS (20mg/kg, IV)
+15 more
Locations
13
United States
Bridge HIV CRS
San Francisco, California, United States
George Washington University
Washington D.C., District of Columbia, United States
The Hope Clinic of the Emory Vaccine Center
Atlanta, Georgia, United States
New Jersey Medical School Clinical Research Center CRS
Newark, New Jersey, United States
Vanderbilt Vaccine (VV)
Nashville, Tennessee, United States
Kenya Medical Research Institute (KEMRI)
Kericho, Kenya
Start Date
November 15, 2021
Primary Completion Date
July 19, 2023
Completion Date
July 19, 2023
Last Updated
February 10, 2025
NCT04142047
NCT06694805
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions